Kiselak Tomas
- SEC CIK
- 0001830177
In the past year, 4 open-market purchase filings worth $39.6M and 3 sale filings worth $833.2M.
Current role at each company
- KRSA Korsana Biosciences, Inc.Director, 10% Owneras of Sep 10, 2026
- CIK 0001974640Directoras of Sep 3, 2026
- CBIO Crescent Biopharma, Inc.Director, 10% Owneras of Jul 20, 2026
- VRDN Viridian Therapeutics, Inc.Directoras of Jul 2, 2026
- ORKA Oruka Therapeutics, Inc.Director, 10% Owneras of Jul 1, 2026
Show 5 more companies
- SYRE Spyre Therapeutics, Inc.Directoras of Jun 23, 2026
- JBIO Jade Biosciences, Inc.Director, 10% Owneras of Jun 11, 2026
- ZBIO Zenas BioPharma, Inc.Directoras of Apr 1, 2026
- DMRA Damora Therapeutics, Inc.10% Owneras of Mar 25, 2026
- DNTH Dianthus Therapeutics, Inc.Directoras of Oct 1, 2024
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- $39.6M
- 4 filings
- Sold
- $833.2M
- 3 filings
- Net
- −$793.6M
- Bought minus sold
- Companies
- 5
- With open-market trades
Trades
Every Form 4 that lists Kiselak Tomas as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
CBIO Crescent Biopharma, Inc.
Director, 10% Owner4 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 20, 2026 (view filing)5:30 PM ET | Jul 16 | 4 days | Harwin Peter Evan and 3 othersDirector, 10% Owner | PPurchase | +853.5K | $14.50 | +$12.4M | +31.1%3.60M after | |
| Jul 20, 2026 (view filing)5:30 PM ET | Jul 16 | 4 days | Harwin Peter Evan and 3 othersDirector, 10% Owner | PPurchase | +525.9K | $14.50 | +$7.62M | –2.29M after | Derivative |
| Dec 8, 2025 (view filing)4:30 PM ET | Dec 4 | 4 days | Harwin Peter Evan and 3 othersDirector, 10% Owner | PPurchase | +1.36M | $13.41 | +$18.2M | +98.0%2.75M after | |
| Dec 8, 2025 (view filing)4:30 PM ET | Dec 4 | 4 days | Harwin Peter Evan and 3 othersDirector, 10% Owner | PPurchase | +131.4K | $13.41 | +$1.76M | –1.77M after | Derivative |
ORKA Oruka Therapeutics, Inc.
Director, 10% Owner1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 1, 2026 (view filing)9:30 PM ET | Jul 1 | Same day | Harwin Peter Evan and 4 othersDirector, 10% Owner | SSale | −3.55M | $84.43 | −$300.0M | −75.8%1.13M after |
SYRE Spyre Therapeutics, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 23, 2026 (view filing)9:56 PM ET | Jun 23 | Same day | Harwin Peter Evan and 3 othersDirector | SSale | −4.68M | $85.31 | −$399.7M | −100.0%0 after |
ZBIO Zenas BioPharma, Inc.
Director3 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 1, 2026 (view filing)4:30 PM ET | Mar 31 | 1 day | Harwin Peter Evan and 3 othersDirector | PPurchase | +150.0K | $20.00 | +$3.00M | +6.8%2.36M after | |
| Oct 9, 2025 (view filing)4:15 PM ET | Oct 7 | 2 days | Harwin Peter Evan and 3 othersDirector | PPurchase | +316.2K | $19.00 | +$6.01M | +16.7%2.21M after | |
| Sep 17, 2024 (view filing)8:56 PM ET | Sep 16 | 1 day | Harwin Peter Evan and 3 othersDirector | PPurchase | +300.0K | $17.00 | +$5.10M | +18.8%1.89M after | Amended |
CIK 0001974640
Director2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 22, 2026 (view filing)8:07 PM ET | Jan 22 | Same day | Harwin Peter Evan and 3 othersDirector | SSale | −1.75M | $76.30 | −$133.5M | −85.4%298.6K after | |
| Jul 17, 2023 (view filing)8:00 PM ET | Jul 13 | 4 days | Harwin Peter Evan and 5 othersDirector | PPurchase | +2.94M | $17.00 | +$50.0M | New position892.5K after | 3 lots |
DNTH Dianthus Therapeutics, Inc.
Director4 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 3, 2023 (view filing)4:00 PM ET | Sep 29 | 4 days | Harwin Peter Evan and 2 othersDirector, 10% Owner | PPurchase | +24.7K | $13.63 | +$336.3K | +1.3%1.93M after | |
| Sep 28, 2023 (view filing)5:09 PM ET | Sep 26 | 2 days | Harwin Peter Evan and 2 othersDirector, 10% Owner | PPurchase | +30.0K | $13.15 | +$394.5K | +1.6%1.90M after | |
| Sep 21, 2023 (view filing)4:23 PM ET | Sep 19 | 2 days | Harwin Peter Evan and 2 othersDirector, 10% Owner | PPurchase | +30.0K | $13.20 | +$396.0K | +1.6%1.87M after | |
| Sep 13, 2023 (view filing)9:17 PM ET | Sep 12-13 | 1 day | Harwin Peter Evan and 2 othersDirector, 10% Owner | PPurchase | +24.3K | $11.20 | +$271.7K | +1.3%1.84M after | 2 lots |